PT - JOURNAL ARTICLE AU - Ville Karhunen AU - Dipender Gill AU - Rainer Malik AU - Mark J. Ponsford AU - Ari Ahola-Olli AU - Areti Papadopoulou AU - Saranya Palaniswamy AU - Shivaprakash Jagalur Mutt AU - Sylvain Sebert AU - Minna Männikkö AU - Juha Auvinen AU - Juha Veijola AU - Karl-Heinz Herzig AU - Markku Timonen AU - Sirkka Keinänen-Kiukaanniemi AU - Martin Dichgans AU - Marko Salmi AU - Sirpa Jalkanen AU - Terho Lehtimäki AU - Veikko Salomaa AU - Olli Raitakari AU - Simon A Jones AU - Konstantinos K. Tsilidis AU - Marjo-Riitta Järvelin AU - Abbas Dehghan TI - Genetic study of circulating cytokines offers insight into the determinants, cascades and effects of systemic inflammation AID - 10.1101/2020.10.26.20219477 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.26.20219477 4099 - http://medrxiv.org/content/early/2020/10/31/2020.10.26.20219477.short 4100 - http://medrxiv.org/content/early/2020/10/31/2020.10.26.20219477.full AB - Cytokines are the signalling molecules that underlie inflammatory processes. Here, we performed genome-wide association study (GWAS) analyses of 47 circulating cytokines in up to 13,365 individuals to identify protein quantitative trait loci (pQTL). Applying a novel approach, we incorporated pQTL and expression quantitative trait loci (eQTL) data of 10,361 tissue samples in 635 individuals to identify biologically plausible genetic instruments to proxy the effect of cytokines. Using Mendelian randomization analysis, we explored the causal determinants of inflammatory cytokines, investigated inflammatory cascades and evaluated their effects on 20 diseases. We show evidence of body mass index (BMI), smoking and systolic blood pressure (SBP) being associated with inflammation, and specifically BMI affecting levels of active PAI-1, HGF, MCP1, sE-Selectin, sICAM1, TRAIL, IL6 and CRP. Our analysis highlights a key role of VEGF in influencing the levels of eight other inflammatory cytokines. Finally, we report evidence of sICAM affecting waist circumference and risk of major depressive disorder, evidence for TRAIL affecting the risk of cardiovascular diseases, breast and prostate cancer, and evidence for MIG affecting the risk of stroke. Overall, our results offer insight into inflammatory mediators of BMI, smoking and SBP, pleiotropic effects of VEGF, and circulating cytokines that increase the risk of cancer, cardiovascular, metabolic and neuropsychiatric diseases. All the studied cytokines represent pharmacological targets and therefore offer opportunities for clinical translation in diseases with inflammatory components.Competing Interest StatementDG is employed part-time by Novo Nordisk. VS has received honoraria from Novo Nordisk and Sanofi for consultations and travel support from Novo Nordisk. He also has ongoing research collaboration with Bayer Ltd. These are all unrelated to the present study. The remaining authors have no conflicts of interest to declare.Funding StatementVK is funded by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). DG was supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. MP is a funded by the Welsh Clinical Academic Training (WCAT) programme and is a participant in the NIH Graduate Partnership Program. VS was supported by the Finnish Foundation for Cardiovascular Research. SP is funded by the the European Union's Horizon 2020 Framework EDCMET (825762), iHealth-T2D (643774), Yrjo Jahnsson Foundation and Paivikki and Sakari Sohlberg Foundation. KKT was supported by Cancer Research UK (C18281/A29019). MRJ is funded by the European Union's Horizon 2020 programmes: EDCMET (825762), DynaHEALTH (633595), LifeCycle, iHealth-T2D (643774), LongITools (874739) and Medical Research Council/Biotechnology and Biological Sciences Research Council (PREcisE, MR/M013138/1, MR/S03658X/1, under Nutrition & Epigenome, The Joint Programming Initiative a Healthy Diet for a Healthy Life (JPI HDHL/EU-H2020, project number 665)). AD is funded by the Wellcome Trust seed award (206046/Z/17/Z). This project has also received funding from the European Union's Horizon 2020 research and innovation programme (666881), SVDs@target (to MD; 667375), CoSTREAM (to MD); the DFG as part of the Munich Cluster for Systems Neurology (SyNergy, EXC EXC 2145 SyNergy - ID 390857198), the CRC 1123 (B3; to MD) and project DI 722/13-1; the Corona Foundation (to MD); the LMUexcellent fond (to MD); the e:Med program (e:AtheroSysMed; to MD) and the FP7/2007-2103 European Union project CVgenes@target (grant agreement number Health-F2-2013-601456; to MD). NFBC1966 received core funding for data generation and curation from the Academy of Finland (285547 (EGEA)), University Hospital Oulu, Finland (65354, 75617), Biocenter Oulu, Finland. The NFBCs are also funded by EU-H2020 EUCAN Connect (824989). The Young Finns Study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (755320 for TAXINOMISIS and 848146 for To Aition); European Research Council (742927 for MULTIEPIGEN project); and Tampere University Hospital Supporting Foundation. The original cytokine measurements were funded by Academy of Finland (141136). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study cohorts used in this work had already obtained relevant ethical approval and written participant consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll supporting data for this work are available within the article, its supplementary files and the citations provided. The GWAS summary statistics generated in this work will be made publicly available upon the publication of the article. All study cohorts used in this work had already obtained relevant ethical approval and written participant consent.